Advertisement

NPY in alcoholism and psychiatric disorders

  • Annika Thorsell
  • Rose-Marie Karlsson
  • Markus Heilig
Part of the Experientia Supplementum book series (EXS, volume 95)

Conclusion

The NPY system may well be one of the most interesting target systems for development of treatments for alcohol dependence as well as mood disorders such as depression and anxiety syndromes. NPY is an endogenous anxiolytic compound, functions as an antidepressant, and is effective in modifying alcohol intake in high drinking states. Through receptor subtype specific compounds, the NPY system offers an interesting and innovative future approach for treatment designs. Selective Y2 receptor antagonists and/or Y1 agonists that are peripherally available and effectively penetrate the CNS are possible candidates. In conclusion, the NPY system offers attractive targets for development of future treatments for depression, anxiety, and alcohol dependence.

Keywords

Ethanol Intake Alko Alcohol High Alcohol Drinking Dorsal Periaqueductal Gray Matter Electroconvulsive Stimulus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477–501CrossRefPubMedGoogle Scholar
  2. 2.
    Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ (1992) Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry 49: 716–722PubMedGoogle Scholar
  3. 3.
    Sullivan PF, Kendler KS (1998) Typology of common psychiatric syndromes. An empirical study. Br J Psychiatry 173: 312–319PubMedGoogle Scholar
  4. 4.
    Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL (1995) Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6: 215–222PubMedGoogle Scholar
  5. 5.
    Heilig M, Soderpalm B, Engel JA, Widerlov E (1989) Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 98: 524–529Google Scholar
  6. 6.
    Sajdyk TJ, Vandergriff MG, Gehlert DR (1999) Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 368: 143–147CrossRefPubMedGoogle Scholar
  7. 7.
    Heilig M, McLeod S, Koob GK, Britton KT (1992) Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41: 61–69CrossRefPubMedGoogle Scholar
  8. 8.
    Tovote P, Meyer M, Beck-Sickinger AG, von HS, Ove OS, Spiess J, Stiedl O (2004) Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. Regul Pept 120: 205–214CrossRefPubMedGoogle Scholar
  9. 9.
    Heilig M, Murison R (1987) Intracerebroventricular neuropeptide Y protects against stressinduced gastric erosion in the rat. Eur J Pharmacol 137: 127–129CrossRefPubMedGoogle Scholar
  10. 10.
    Bannon AW, Seda J, Carmouche M, Francis JM, Norman MH, Karbon B, McCaleb ML (2000) Behavioral characterization of neuropeptide Y knockout mice. Brain Res 868: 79–87CrossRefPubMedGoogle Scholar
  11. 11.
    Thiele TE, Marsh DJ, Ste ML, Bernstein IL, Palmiter RD (1998) Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 396: 366–369CrossRefPubMedGoogle Scholar
  12. 12.
    Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, Mathe AA, Heilig M (2000) Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci USA 97: 12852–12857CrossRefPubMedGoogle Scholar
  13. 13.
    Carvajal CC, Vercauteren F, Dumont Y, Michalkiewicz M, Quirion R (2004) Aged neuropeptide Y transgenic rats are resistant to acute stress but maintain spatial and non-spatial learning. Behav Brain Res 153: 471–480CrossRefPubMedGoogle Scholar
  14. 14.
    Thorsell A, Svensson P, Wiklund L, Sommer W, Ekman R, Heilig M (1998) Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul Pept 75–76: 247–254PubMedGoogle Scholar
  15. 15.
    Thorsell A, Carlsson K, Ekman R, Heilig M (1999) Behavioral and endocrine adaptation, and upregulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 10: 3003–3007PubMedGoogle Scholar
  16. 16.
    Heilig M, Thorsell A (2002) Brain neuropeptide Y (NPY) in stress and alcohol dependence. Rev Neurosci 13: 85–94PubMedGoogle Scholar
  17. 17.
    Caberlotto L, Fuxe K, Overstreet DH, Gerrard P, Hurd YL (1998) Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res Mol Brain Res 59: 58–65PubMedGoogle Scholar
  18. 18.
    Caberlotto L, Jimenez P, Overstreet DH, Hurd YL, Mathe AA, Fuxe K (1999) Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression. Neurosci Lett 265: 191–194CrossRefPubMedGoogle Scholar
  19. 19.
    Jimenez-Vasquez PA, Overstreet DH, Mathe AA (2000) Neuropeptide Y in male and female brains of Flinders Sensitive Line, a rat model of depression. Effects of electroconvulsive stimuli. J Psychiatr Res 34: 405–412PubMedGoogle Scholar
  20. 20.
    Jimenez Vasquez PA, Salmi P, Ahlenius S, Mathe AA (2000) Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion. Behav Brain Res 111: 115–123PubMedGoogle Scholar
  21. 21.
    Wahlestedt C, Karoum F, Jaskiw G, Wyatt RJ, Larhammar D, Ekman R, Reis DJ (1991) Cocaineinduced reduction of brain neuropeptide Y synthesis dependent on medial prefrontal cortex. Proc Natl Acad Sci USA 88: 2078–2082PubMedGoogle Scholar
  22. 22.
    Heilig M, Wahlestedt C, Ekman R, Widerlöv E (1988) Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. European Journal of Pharmacology 147: 465–467CrossRefPubMedGoogle Scholar
  23. 23.
    Heilig M, Ekman R (1995) Chronic parenteral antidepressant treatment in rats: unaltered levels and processing of neuropeptide Y (NPY) and corticotropin-releasing hormone (CRH). Neurochem Int 26: 351–355CrossRefPubMedGoogle Scholar
  24. 24.
    Bellman R, Sperk G (1993) Effects of antidepressant drug treatment on levels of NPY or prepro-NPY-mRNA in the rat brain. Neurochemistry International 22: 183–187Google Scholar
  25. 25.
    Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS (1995) Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology (Berl) 121: 27–37Google Scholar
  26. 26.
    Mathe AA, Gruber S, Jimenez PA, Theodorsson E, Stenfors C (1997) Effects of electroconvulsive stimuli and MK-801 on neuropeptide Y, neurokinin A, and calcitonin gene-related peptide in rat brain. Neurochem Res 22: 629–636PubMedGoogle Scholar
  27. 27.
    Mathe AA, Jimenez PA, Theodorsson E, Stenfors C (1998) Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded “depressed”, Wistar, and Sprague Dawley rats. Effects of electroconvulsive stimuli. Prog Neuropsychopharmacol Biol Psychiatry 22: 529–546CrossRefPubMedGoogle Scholar
  28. 28.
    Wahlestedt C, Blendy JA, Kellar KJ, Heilig M, Widerlov E, Ekman R (1990) Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat. Brain Res 507: 65–68CrossRefPubMedGoogle Scholar
  29. 29.
    Husum H, Gruber SH, Bolwig TG, Mathe AA (2002) Extracellular levels of NPY in the dorsal hippocampus of freely moving rats are markedly elevated following a single electroconvulsive stimulation, irrespective of anticonvulsive Y1 receptor blockade. Neuropeptides 36: 363–369CrossRefPubMedGoogle Scholar
  30. 30.
    Husum H, Mikkelsen JD, Hogg S, Mathe AA, Mork A (2000) Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 39: 1463–1473CrossRefPubMedGoogle Scholar
  31. 31.
    Zachrisson O, Mathe AA, Stenfors C, Lindefors N (1995) Limbic effects of repeated electroconvulsive stimulation on neuropeptide Y and somatostatin mRNA expression in the rat brain. Brain Res Mol Brain Res 31: 71–85PubMedGoogle Scholar
  32. 32.
    Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M (1993) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259: 528–531PubMedGoogle Scholar
  33. 33.
    King PJ, Williams G, Doods H, Widdowson PS (2000) Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol 396: R1–R3CrossRefPubMedGoogle Scholar
  34. 34.
    King PJ, Widdowson PS, Doods HN, Williams G (1999) Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem 73: 641–646CrossRefPubMedGoogle Scholar
  35. 35.
    Redrobe JP, Dumont Y, Herzog H, Quirion R (2003) Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav Brain Res 141: 251–255CrossRefPubMedGoogle Scholar
  36. 36.
    Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, Herzog H, Sperk G (2003) Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 18: 143–148CrossRefPubMedGoogle Scholar
  37. 37.
    Sajdyk TJ, Schober DA, Gehlert DR (2002) Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology 43: 1165–1172CrossRefPubMedGoogle Scholar
  38. 38.
    Sajdyk TJ, Schober DA, Smiley DL, Gehlert DR (2002) Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav 71: 419–423CrossRefPubMedGoogle Scholar
  39. 39.
    Kask A, Eller M, Oreland L, Harro J (2000) Neuropeptide Y attenuates the effect of locus coeruleus denervation by DSP-4 treatment on social behaviour in the rat. Neuropeptides 34: 58–61CrossRefPubMedGoogle Scholar
  40. 40.
    Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT (1993) Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 8: 357–363PubMedGoogle Scholar
  41. 41.
    Brandao ML (1993) Involvement of opioid mechanisms in the dorsal periaqueductal gray in drug abuse. Rev Neurosci 4: 397–405PubMedGoogle Scholar
  42. 42.
    Fendt M, Fanselow MS (1999) The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 23: 743–760CrossRefPubMedGoogle Scholar
  43. 43.
    Kask A, Rago L, Harro J (1998) Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regul Pept 75–76: 255–262PubMedGoogle Scholar
  44. 44.
    Kask A, Rago L, Harro J (1998) NPY Y1 receptors in the dorsal periaqueductal gray matter regulate anxiety in the social interaction test. Neuroreport 9: 2713–2716PubMedGoogle Scholar
  45. 45.
    Lee Y, Davis M (1997) Role of the septum in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J Neurosci 17: 6424–6433PubMedGoogle Scholar
  46. 46.
    Andrews N, File SE, Fernandes C, Gonzalez LE, Barnes NM (1997) Evidence that the median raphe nucleus-dorsal hippocampal pathway mediates diazepam withdrawal-induced anxiety. Psychopharmacology (Berl) 130: 228–234Google Scholar
  47. 47.
    Gonzalez LE, Ouagazzal AM, File SE (1998) Stimulation of benzodiazepine receptors in the dorsal hippocampus and median raphe reveals differential GABAergic control in two animal tests of anxiety. Eur J Neurosci 10: 3673–3680CrossRefPubMedGoogle Scholar
  48. 48.
    Kask A, Nguyen HP, Pabst R, von HS (2001) Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormoneinduced anxiety. Neuroscience 104: 799–806CrossRefPubMedGoogle Scholar
  49. 49.
    Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R (1988) Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22: 69–79PubMedGoogle Scholar
  50. 50.
    Widdowson PS, Ordway GA, Halaris AE (1992) Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 59: 73–80PubMedGoogle Scholar
  51. 51.
    Berrettini WH, Doran AR, Kelsoe J, Roy A, Pickar D (1987) Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. Neuropsychopharmacology 1: 81–83CrossRefPubMedGoogle Scholar
  52. 52.
    Ordway GA, Stockmeier CA, Meltzer HY, Overholser JC, Jaconetta S, Widdowson PS (1995) Neuropeptide Y in frontal cortex is not altered in major depression. J Neurochem 65: 1646–1650PubMedGoogle Scholar
  53. 53.
    Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagui-Tabar S, Sjogren M, Asberg M, Ekman R, Wahlestedt C, Agren H (2004) Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 38: 113–121CrossRefPubMedGoogle Scholar
  54. 54.
    Caberlotto L, Hurd YL (1999) Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. Neuroreport 10: 1747–1750PubMedGoogle Scholar
  55. 55.
    Pandey SC (2003) Anxiety and alcohol abuse disorders: A common role for CREB and its target, the neuropeptide Y gene. Trends Pharmacol Sci 24: 456–460CrossRefPubMedGoogle Scholar
  56. 56.
    Pandey SC, Carr LG, Heilig M, Ilveskoski E, Thiele TE (2003) Neuropeptide y and alcoholism: Genetic, molecular, and pharmacological evidence. Alcohol Clin Exp Res 27: 149–154PubMedGoogle Scholar
  57. 57.
    Bice P, Foroud T, Bo R, Castelluccio P, Lumeng L, Li TK, Carr LG (1998) Genomic screen for QTLs underlying alcohol consumption in the P and NP rat lines. Mamm Genome 9: 949–955CrossRefPubMedGoogle Scholar
  58. 58.
    Carr LG, Foroud T, Bice P, Gobbett T, Ivashina J, Edenberg H, Lumeng L, Li TK (1998) A quantitative trait locus for alcohol consumption in selectively bred rat lines. Alcohol Clin Exp Res 22: 884–887PubMedGoogle Scholar
  59. 59.
    Kauhanen J, Karvonen MK, Pesonen U, Koulu M, Tuomainen TP, Uusitupa MI, Salonen JT (2000) Neuropeptide Y polymorphism and alcohol consumption in middle-aged men. Am J Med Genet 93: 117–121CrossRefPubMedGoogle Scholar
  60. 60.
    Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker JM, Hart LM, Valve R, Uusitupa MIJ (1998) Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nature Medicine 4: 1434–1437CrossRefPubMedGoogle Scholar
  61. 61.
    Ilveskoski E, Kajander OA, Lehtimaki T, Kunnas T, Karhunen PJ, Heinala P, Virkkunen M, Alho H (2001) Association of neuropeptide y polymorphism with the occurrence of type 1 and type 2 alcoholism. Alcohol Clin Exp Res 25: 1420–1422PubMedGoogle Scholar
  62. 62.
    Zhu G, Pollak L, Mottagui-Tabar S, Wahlestedt C, Taubman J, Virkkunen M, Goldman D, Heilig M (2003) NPY Leu7Pro and alcohol dependence in Finnish and Swedish populations. Alcohol Clin Exp Res 27: 19–24PubMedGoogle Scholar
  63. 63.
    Okubo T, Harada S (2001) Polymorphism of the neuropeptide Y gene: An association study with alcohol withdrawal. Alcohol Clin Exp Res 25: 59S–62SPubMedGoogle Scholar
  64. 64.
    Li TK, Lumeng L, McBride WJ, Murphy JM (1987) Rodent lines selected for factors affecting alcohol consumption. Alcohol and Alcoholism Suppl 1: 91–96Google Scholar
  65. 65.
    Murphy JM, Stewart RB, Bell RL, Badia-Elder NE, Carr LG, McBride WJ, Lumeng L, Li TK (2002) Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference. Behav Genet 32: 363–388CrossRefPubMedGoogle Scholar
  66. 66.
    Ehlers CL, Li TK, Lumeng L, Hwang BH, Somes C, Jimenez P, Mathe AA (1998) Neuropeptide Y levels in ethanol-naive alcohol-preferring and nonpreferring rats and in Wistar rats after ethanol exposure. Alcohol Clin Exp Res 22: 1778–1782PubMedGoogle Scholar
  67. 67.
    Hwang BH, Zhang JK, Ehlers CL, Lumeng L, Li TK (1999) Innate differences of neuropeptide Y (NPY) in hypothalamic nuclei and central nucleus of the amygdala between selectively bred rats with high and low alcohol preference. Alcohol Clin Exp Res 23: 1023–1030PubMedGoogle Scholar
  68. 68.
    Caberlotto L, Thorsell A, Rimondini R, Sommer W, Hyytia P, Heilig M (2001) Differential expression of NPY and its receptors in alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol Clin Exp Res 25: 1564–1569PubMedGoogle Scholar
  69. 69.
    Katner SN, Slawecki CJ, Ehlers CL (2002) Neuropeptide Y administration into the amygdala does not affect ethanol consumption. Alcohol 28: 29–38CrossRefPubMedGoogle Scholar
  70. 70.
    Katner SN, Slawecki CJ, Ehlers CL (2002) Neuropeptide Y administration into the third ventricle does not increase sucrose or ethanol self-administration but does affect the cortical EEG and increases food intake. Psychopharmacology (Berl) 160: 146–154Google Scholar
  71. 71.
    Badia-Elder NE, Stewart RB, Powrozek TA, Roy KF, Murphy JM, Li TK (2001) Effect of neuropeptide Y (NPY) on oral ethanol intake in Wistar, alcohol-preferring (P), and-nonpreferring (NP) rats. Alcohol Clin Exp Res 25: 386–390PubMedGoogle Scholar
  72. 72.
    Slawecki CJ, Betancourt M, Walpole T, Ehlers CL (2000) Increases in sucrose consumption, but not ethanol consumption, following ICV NPY administration. Pharmacol Biochem Behav 66: 591–594CrossRefPubMedGoogle Scholar
  73. 73.
    Badia-Elder NE, Stewart RB, Powrozek TA, Murphy JM, Li TK (2003) Effects of neuropeptide Y on sucrose and ethanol intake and on anxiety-like behavior in high alcohol drinking (HAD) and low alcohol drinking (LAD) rats. Alcohol Clin Exp Res 27: 894–899PubMedGoogle Scholar
  74. 74.
    Kelley SP, Nannini MA, Bratt AM, Hodge CW (2001) Neuropeptide-Y in the paraventricular nucleus increases ethanol self-administration. Peptides 22: 515–522CrossRefPubMedGoogle Scholar
  75. 75.
    Gilpin NW, Stewart RB, Murphy JM, Badia-Elder NE (2004) Neuropeptide Y in the paraventricular nucleus of the hypothalamus increases ethanol intake in high-and low-alcohol-drinking rats. Alcohol Clin Exp Res 28: 1492–1498PubMedGoogle Scholar
  76. 76.
    Rimondini R, Arlinde C, Sommer W, Heilig M (2002) Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. FASEB J 16: 27–35CrossRefPubMedGoogle Scholar
  77. 77.
    Thorsell A, Slawecki CJ, Ehlers CL (2005) Effects of neuropeptide Y and corticotropin-releasing factor on ethanol intake in Wistar rats: Interaction with chronic ethanol exposure. Behav Brain Res 161: 133–140CrossRefPubMedGoogle Scholar
  78. 78.
    Thiele TE, Koh MT, Pedrazzini T (2002) Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J Neurosci 22: 1–6Google Scholar
  79. 79.
    Thorsell A, Rimondini R, Heilig M (2002) Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats. Neurosci Lett 332: 1–4CrossRefPubMedGoogle Scholar
  80. 80.
    Rimondini R, Thorsell A, Heilig M (2005) Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: Evidence for sensitization in rats with a history of dependence. Neurosci Lett 375: 129–133CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2006

Authors and Affiliations

  • Annika Thorsell
    • 1
  • Rose-Marie Karlsson
    • 1
  • Markus Heilig
    • 1
  1. 1.NIH/NIAAA, LCSBethesdaUSA

Personalised recommendations